Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius + vitamin D + zinc
- Development stage
- Unknown
- Lead developer
- Wakamoto
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination is a multi-ingredient nutraceutical formulation designed to support oral health and mucosal immunity. **Lactobacillus salivarius** is a probiotic bacterium that colonizes the oral cavity and gastrointestinal tract, where it exerts antimicrobial effects against pathogens such as *Porphyromonas gingivalis* and *Streptococcus mutans* through competitive exclusion and the production of bacteriocins (e.g., salivaricins). **Vitamin D** (typically as cholecalciferol) acts as a ligand for the Vitamin D receptor (VDR), stimulating the innate immune system to produce antimicrobial peptides like cathelicidins and defensins. **Zinc** serves as an essential mineral cofactor for over 300 enzymes, playing a critical role in DNA synthesis, cell division, and the maintenance of the oral epithelial barrier. The combination is primarily utilized in the management of halitosis, gingivitis, and as an adjunct in periodontal therapy.
- Other names
- lactobacillus salivarius + cholecalciferol + zincL. salivarius + Vitamin D3 + Zinc
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on lactobacillus salivarius + vitamin D + zinc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius + vitamin D + zinc.